Connect with us

BUSINESS

Heritage Cannabis Holdings Corporation (OTCQX: HERFT) Provides an Update on its Canadian Recreational Department and its Branded CB4 Medical Products

Published

on

Heritage Cannabis Holdings Corporation (QTCQX: HERTF) is happy to talk about the growth of its recreational products in Canada. The company has continued its robust execution in Q3. Heritage’s Q2 results indicated how strong its strategy was proving to be as it posted a quarter-over-quarter 250% increase in revenue. In addition, Heritage has continued to execute its strategy. Because of this, it has seen many of its Heritage Brands fill shelves all across the region. This is an accomplishment as most corporations are witnessing a reduction in shelf spaces in the region, given how crowded the landscape is right now. 

Recreational Sales

Ontario- In Canada’s most crowded and largest market, the company continues to witness growing interests in its affordably priced and premium products, with seven new SKUs introduced in Q3. In the concentrates department, RAD Shatter brands happened to be the fastest-growing goods and achieved #6 and #5 overall concentrate within a month of the product’s launch. In addition to all this, Heritage saw a 40% increase in its month-over-month sales revenue in the oils department and a 164% increase in vape sales. 

Western Canada- Recurring and sales orders in British Columbia for Heritage brands continued to grow, with quarter-over-quarter growth of about 119% in vape sales. Currently, RAD goods are in almost every dispensary in the region. In addition, the company has transported its first RAD Doobie and RAD Flower orders and expects to make further shipments to other provinces by the fourth quarter. 

Quebec- The company has entered into a supply partnership with Medicibis, a Quebec-based company, to supply 61 SKUs to its Mendocannabis.ca medical platform. Additionally, the company recently took part in product calls with (SQDC) Societe Quebecoise du Cannabis.   

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

Heritage Cannabis Holdings Corp (OTCMKTS: HERTF) And Avicanna Inc. Enter Product Licensing and Royalty Agreement

Published

on

Heritage Cannabis Holdings Corp (OTCMKTS: HERTF) has signed an exclusive IP licensing and royalty deal with Avicanna Inc. Avicanna is a biopharmaceutical firm specializing in the development, production, and marketing of plant-derived CBD products. 

Heritage to avail Avicanna products on Q4 

The Licensing Agreement covers the marketing of Avicanna’s advanced CBD-based topical treatments under Heritage’s medical cannabis brands. Avicanna’s patented cannabis topical products, created years of comprehensive research by the company’s scientists, are among the Branded Products. The formulations are supported with pre-clinical research, including two SKUs backed with complete human trials. Heritage’s vast medical sales channels across Canada will introduce the Branded Products in Q4 2021.

Umar Syed, Heritage’s president for the medical division, commented, “We are excited to add Avicanna’s innovative topical products to our portfolio of highly effective medical CBD products. They are a great strategic fit. We are very impressed with Avicanna’s diligent R&D approach for developing highly effective topical products formulated with pharmaceutical technology and which are supported with evidence of efficacy, much like the existing Opticann portfolio that includes oral products that use the patented VESIsorb technology and sublingual CBD filmstrips that use the patented Versafilm technology. The Licensing Agreement offers Heritage speed-to-market with highly effective topicals and we see this as the beginning of a highly successful commercial partnership.”

Avicanna to receive royalty payment on sales 

Avicanna has exclusively licensed, subject to certain conditions and exceptions, the use of certain proprietary product formulations to Heritage to be sold and marketed under Heritage’s medical Opticann branded products throughout Canada under the terms of the Licensing Agreement. The agreement has an initial three-year period. In addition, heritage must reach specified annual sales targets for each Branded Product licensed under the Licensing Agreement, and it will pay Avicanna a royalty for products sold.

Aras Azadian, Avicanna CEO, said, “We look forward to collaborating with the Heritage team to extend our proprietary and evidence-based topical formulations to more Canadian patients and expand into more medical channels nationwide.”

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Revive Therapeutics Ltd (OTCMKTS: RVVTF) Updates About its Programs, and Cartel Blue Ord Shs (OTCMKTS: CRTL) Announces Launch of Premium Hemp Cigar Lounges and Product Showrooms

Published

on

Revive Therapeutics Ltd (OTCMKTS: RVVTF) announced an update regarding its psilocybin focussed psychedelics development and clinical programs. The specialty life sciences company works on research and development therapeutics for medical needs and rare disorders. 

The company aims to unlock the potential therapeutic value of psilocybin

Michael Frank, CEO of Revive Therapeutics Ltd stated that the company is working on clinical studies to open the actual potential therapeutic value of psilocybin in its multiple uses, besides working on ways to treat mental health, substance abuse, and neurological disorders. 

The CEO went on record and stated that the company is headed towards its next growth stage, focusing on entering into a partnership with U.S. academic institutions and other organizations. The company is also developing intellectual property and venturing into FDA clinical studies with psilocybin, stated the CEO. 

Development of Psilocybin oral thin-film strip underway

As part of a feasibility agreement with LTS Lohmann Therapie-Systeme AG, the company has started its product development program. Under the initiative, the development and manufacturing of a proprietary psilocybin oral thin-film strip will be done. The product can be used to treat substance abuse, mental illness, and neurological disorders. Clinical studies will be conducted in 2022. 

Cartel Blue Ord Shs (OTCMKTS: CRTL) confirms launch of premium hemp cigar lounges and product showrooms

Cartel Blue Ord Shs (OTCMKTS: CRTL) announced the launch of its first premium hemp cigar lounges and its product showrooms. According to a statement issued by the company, the three Cartel Premium Cigar Lounges will be opened in Nashville, Cathedral City, and Honolulu. As a result, the Premium Hemp smoker can take advantage of Cartel products in a secure and comfortable environment at the new locations. 

It is learned that Cartel Blue Ord Shs will be granted the liquescence to sell products with Hawaii Grown and Product of the Kingdom of Hawaii trademarks in locations where Cartel Blue products are marketed and sold. Additionally, a source from the company shared that Alan Ada of Pointe West Pacific Development is responsible for the construction, expansion, and management of all the facilities in line with the Cartels business model.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Pharmacyte Biotech Inc (NASDAQ: PMCB) IOP Closes and the Company’s Common Stock Begins to Trade on NASDAQ

Published

on

Pharmacyte Biotech Inc (NASDAQ: PMCB) announced the closure of underwritten public offering valued at $15 million. The company’s stock are currently trading on NASDAQ.

H.C. Wainwright appointed as sole book-running manager

The company chose to have H.C. Wainwright as its sole book-running manager for the offering. A written prospectus, prospectus supplement about the offering and registration statement on Form S-3 (File No. 333-255044) that was previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (SEC) on April 14, 2021, were filed as part of the offering. 

A source from the company shared that the final prospectus supplement and accompanying prospectus on the offer is filed with the SEC, besides being available on SEC’s official website. In addition, electronic copies of the prospectus could be obtained, the source added. 

Information about the IPO

More than 3.5 million shares of the company’s common stock and warrants to purchase up to an aggregate of the same number of common stock were part of the IPO. Besides this, the company granted the underwriter an option of 30-days to purchase additional shares of its common stock, besides being given a choice to buy accompanying company warrants. 

After deducting underwriting discounts, commissions, and other offering expenses, Pharmacyte Biotech Inc earned net proceeds of around $13.6 million from the IPO during closure. 

Pharmacyte Biotech Inc stock begins to trade 

Pharmacyte Biotech Inc stock begins to trade on the Nasdaq Capital Market. The IPO offering of the company closed, and under the symbol PMCB, the stock of the company commenced its trading journey. The company in the biotechnology sector is developing cellular therapies for cancer and diabetes. The treatments are made based on a cellulose-based live-cell technology christened Cell-in-a-Box®. The team of experts at the company produces various therapies to treat cancer and diabetes. 

Therapies developed by the company convert inactive chemotherapy drugs into cancer-killing form

Therapies developed by Pharmacyte Biotech Inc for cancer involve genetically engineered human cells that are capable of converting an inactive chemotherapy drug into its active or cancer-killing form.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories